

## SUMMARY PRODUCT CHARACTERISTICS

**VISO CN**  
**(Sodium Alginate, Sodium Bicarbonate & Calcium Carbonate Oral Suspension)**



### 1. NAME OF THE MEDICINAL PRODUCT

#### 1.1 Name of the Medicinal Product

VISO CN

Sodium Alginate, Sodium Bicarbonate & Calcium Carbonate Oral Suspension

#### 1.2 Strength

Sodium Alginate BP.....250 mg

Sodium Bicarbonate BP...133.5 mg

Calcium Carbonate.....80 mg

#### 1.3 Pharmaceutical Form

Oral Suspension

### 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each 5 ml solution contains:

Sodium Alginate BP.....250 mg

Sodium Bicarbonate BP...133.5 mg

Calcium Carbonate.....80 mg

Excipients.....q.s.

Flavour: Peppermint

### 3. PHARMACEUTICAL FORM

Oral Suspension

White coloured, peppermint flavoured oral suspension.

### 4. CLINICAL PARTICULARS

#### 4.1. Therapeutic indication

This medicine alleviates the painful conditions resulting from the reflux of gastric acid and bile into the oesophagus by suppressing the reflux itself. It is indicated in heartburn, including heartburn of pregnancy, dyspepsia associated with gastric reflux, hiatus hernia, reflux oesophagitis, regurgitation and all cases of epigastric and retrosternal distress where the underlying cause is gastric reflux.

## SUMMARY PRODUCT CHARACTERISTICS

### VISOCN (Sodium Alginate, Sodium Bicarbonate & Calcium Carbonate Oral Suspension)



#### 4.2. Posology and method of administration

For oral use

Adults and children over 12 years	Two to four 5 ml spoonfuls.
Children 6-12 years	One to two 5 ml spoonfuls

Not recommended in children under six years of age.

Doses should be taken after meals and at bedtime.

#### 4.3. Contra-indications

This medicinal product is contraindicated in patients with known or suspected hypersensitivity to the active substances or to any of the excipients listed in section 6.1.

#### 4.4. Special warnings and special precautions for use

If symptoms do not improve after seven days, the clinical situation should be reviewed.

Each 10 ml dose of this medicine contains about 6 mmoles of sodium and therefore care should be exercised in patients on a sodium restricted diet.

Each 10 ml dose contains 160 mg (1.6 mmol) of calcium carbonate. Care needs to be taken in treating patients with hypercalcaemia, nephrocalcinosis and recurrent calcium containing renal calculi.

This medicine should not be taken within 1 to 2 hours of taking other medicines by mouth, or for more than 2 weeks if symptoms persist.

This medicine should not be used by patients allergic to any of its constituents.

#### 4.5 Interaction with other medicinal products and other forms of interaction

A time-interval of 2 hours should be considered between this medicine intake and the administration of other medicinal products, especially tetracyclines, digoxine, fluoroquinolone, iron salt, ketoconazole, neuroleptics, thyroid hormones, penicillamine, beta-blockers (atenolol, metoprolol, propranolol), glucocorticoid, chloroquine and biphosphonates (diphosphonates) and estramustine. See also 4.4. Antacids may interact with other drugs as they alter the gastric pH which may affect dissolution, solubility or ionisation of the other drug. Antacids reduce the absorption of certain drugs from the following groups: ACE Inhibitors, Analgesics, Antibacterials, Antiepileptics, Antifungals, Antimalarials, Antipsychotics, Bisphosphonates, Lithium and Penicillamine.

## SUMMARY PRODUCT CHARACTERISTICS

### VISO CN (Sodium Alginate, Sodium Bicarbonate & Calcium Carbonate Oral Suspension)



Antacids may increase the pH of the urine and affect the rate of drug elimination. Excretion of basic drugs is decreased whereas acidic drugs are eliminated more rapidly.

Due to effects at the renal level sodium bicarbonate may reduce plasma lithium levels and increase plasma quinidine levels.

#### 4.6. Pregnancy and lactation

##### **Pregnancy:**

Clinical studies in more than 500 pregnant women as well as a large amount of data from postmarketing experience indicate no malformative nor fetotoxicity of the active substances. This medicine can be used during pregnancy, if clinically needed.

##### **Breast feeding:**

No effects of the active substances have been shown in breastfed newborns/infants of treated mothers. This medicine can be used during breast-feeding.

##### **Fertility:**

Pre-clinical investigations have revealed alginate has no negative effect on parental or offspring fertility or reproduction.

Clinical data do not suggest that this medicine has an effect on human fertility.

#### 4.7. Effects on ability to drive and use machines

There are no effects on ability to drive or operate machinery.

#### 4.8. Undesirable Effects

Adverse reactions have been ranked under headings of frequency using the following convention: very common (1/10), common (1/100 and <1/10), uncommon (1/1000 and <1/100), rare (1/10,000 and <1/1000), very rare (< 1/10,000) and not known (cannot be estimated from the available data).

System Organ Class	Frequency	Adverse Event
Immune System Disorders	Very rare	Anaphylactic and anaphylactoid reactions. Hypersensitivity reactions such as urticaria.
Respiratory, Thoracic and Mediastinal Disorders	Very rare	Respiratory effects such as bronchospasm.

## SUMMARY PRODUCT CHARACTERISTICS

**VISO CN**  
**(Sodium Alginate, Sodium Bicarbonate & Calcium Carbonate Oral Suspension)**



### 4.9 Overdose

As this medicine's mode of action is physical, overdosage in terms of the alginate content is virtually no hazard. The only consequence is abdominal distension which is best treated conservatively. The relatively low concentrations of sodium and calcium carbonate in this medicine would also make serious consequences from overdosage very unlikely.

## 5. PHARMACOLOGICAL PROPERTIES

### 5.1 Pharmacodynamic properties

On ingestion the product reacts rapidly with gastric acid to form a raft of alginic acid gel having a near neutral pH and which floats on the stomach contents, quickly and effectively impeding gastroesophageal reflux, for up to 4 hours. In severe cases the raft itself may be refluxed into the oesophagus, in preference to the stomach contents, and exert a demulcent effect.

### 5.2 Pharmacokinetic Properties

Alginic acid is not absorbed into the systemic circulation.

### 5.3. Preclinical safety data

There are no preclinical data of relevance to the prescriber in addition to that included in other sections of the SmPC.

## 6. PHARMACEUTICAL PARTICULARS

### 6.1. List of Excipients

Sodium Methyl Paraben, Sodium Propyl Paraben, Sodium Benzoate, Bronopol, Sodium Saccharine Sorbitol Solution 70 %, Menthol, Propylene Glycol, Colloidal Silicon Dioxide, Flavour: Peppermint & Purified Water.

### 6.2. Incompatibilities

None

### 6.3. Shelf life

36 Months.

## SUMMARY PRODUCT CHARACTERISTICS

**VISO CN**  
**(Sodium Alginate, Sodium Bicarbonate & Calcium Carbonate Oral Suspension)**



### **6.4 Special precautions for storage**

Store below 30°C.

Do not refrigerate or freeze.

Keep out of reach of children

SHAKE WELL BEFORE USE

### **6.5. Nature and contents of container**

150 ml PET Bottles

Pack size: 1 x 150 ml PET Bottles in one carton box along with packing leaflet.

### **6.6. Special precautions for disposal and other handling**

None

### **7.0 Registrant**

**Eastleigh Pharmaceuticals Co. Ltd**

**P.O Box 167-00610 Nairobi, Kenya**

### **8.0 Manufacturer**

**MARS REMEDIES PVT LTD**

**Address: 635, GIDC Estate, Waghodia-391760, Vadodara, GUJARAT INDIA**

### **9.0 Date of Publication or Revision**

Last revised on 04-October-2020

### **10. DOSIMETRY (IF APPLICABLE)**

**Not Applicable**

### **11. Instructions for Preparation of Radiopharmaceuticals (If Applicable):**

**Not Applicable**